The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens,…
Epi Data SLicer
The renal cell carcinoma market is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy…
The renal cell carcinoma market is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy (…
Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy,…
DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology’s coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of renal…
DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key renal cell carcinoma patient populations covering 171 countries and more than…
DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the management of this disease. In a landscape previously dominated by mTOR and…
DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France,…